Sr Associate Scientist, DMPK
Posted on: 9 Apr 2021
Cambridge, MA
Job Description
Job Description
Biogens DMPK department is seeking a highly motivated Sr. Associate Scientist with excellent knowledge and hands-on experience in conducting animal pharmacokinetic (PK) studies to enable discovery and development of innovative therapeutics for people living with serious neurological and neurodegenerative diseases. The successful candidate is expected to conduct PK studies in nonclinical animal species of various modalities including small molecule compounds, monoclonal antibodies, and gene therapy medicinal products (GTMP) to meet potentially challenging needs of projects. The ideal candidate would have experience on developing novel in vivo and ex vivo animal models to solve challenge ADME issues of drug candidates. Ability to perform ligand-binding assays for large molecule quantifications is a plus. Excellent communication and interpersonal skills are required, along with scientific thinking and problem-solving skills. Effectiveness in efficiently engaging other team members in support of team goals is also preferred.
Conduct rodent PK studies on a regular basis with various modalities including small molecule compounds, monoclonal antibodies, and gene therapy medicinal products.
Dosing in mice and rats via the routes including but not limited to IV, PO, SC, IP, IT, and ICV.
Rodent sample collection including but not limited to plasma, serum, urine, cerebrospinal fluid (CSF), brain, spinal cord, and other tissues.
Interface with bioanalytical scientist or outsourcing study manager to deliver and/or ship the rodent samples to CRO in a timely manner.
Interface with Biogen institutional animal care and use committee (IACUC) to write and update experimental protocols.
Opportunities to be trained to perform ligand-binding assays for large molecule quantifications or qPCR/ddPCR assays for GTMP quantifications.
Additional opportunities such as interacting with CROs, contributing to scientific publications, and evaluating emerging in-vivo technologies.
Qualifications
Extensive knowledge and hands-on experience in conducting rodent PK studies on a regular basis.
Hands-on experience with dosing mice and rats via the routes including but not limited to IV, PO, SC, IP, IT, and ICV.
Hands-on experience with rodent sample collection including but not limited to plasma, serum, urine, CSF, brain, spinal cord, and other tissues.
Preferred experience with non-conventional in vivo PK studies such as studies with bile duct cannulated rats or with portal vein cannulated rats.
Hands-on experience in quantification of biologics (e.g. mAb) by ligand-binding assay or LC-MS is a plus.
Experience in studying CNS drug disposition and blood-brain barrier is a plus.
Excellent communication skills and attention to details.
Education:
The successful candidate will have a degree in Biology, Biochemistry, Analytical Chemistry, Pharmaceutical Sciences, or a related field, including a Bachelors degree with at least 4-6 years of experience, or a Masters degree with at least 2-4 years of related industry experience.
Additional Information
All your information will be kept confidential according to EEO guidelines.
Biogen
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
-
IndustryBiotechnology
-
No. of Employees7,800
-
Website
-
Jobs Posted445
